# Trial to Assess the Pharmacokinetics, Safety, Tolerability of Oral Brexpiprazole in Children (6 to <13 Years Old) With Central Nervous System Disorders

> **NCT03292848** · PHASE1 · COMPLETED · sponsor: **Otsuka Pharmaceutical Development & Commercialization, Inc.** · enrollment: 24 (actual)

## Conditions studied

- ADHD
- Autism
- Bipolar I Disorder
- Conduct Disorder
- Oppositional Defiant Disorder

## Interventions

- **DRUG:** Brexpiprazole

## Key facts

- **NCT ID:** NCT03292848
- **Lead sponsor:** Otsuka Pharmaceutical Development & Commercialization, Inc.
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE1
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2017-10-10
- **Primary completion:** 2018-05-21
- **Final completion:** 2018-05-21
- **Target enrollment:** 24 (ACTUAL)
- **Last updated:** 2018-06-12

## Collaborators

- [object Object]

## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT03292848

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT03292848, "Trial to Assess the Pharmacokinetics, Safety, Tolerability of Oral Brexpiprazole in Children (6 to <13 Years Old) With Central Nervous System Disorders". Retrieved via AI Analytics 2026-05-24 from https://api.ai-analytics.org/clinical/NCT03292848. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*